Bayer AG ADR BAYRY
-
UPDATE 3-US advisers reject J&J/ Bayer's Xarelto for acute coronary patients
* FDA advisers concerned about missing data, bleeding risks
-
UPDATE 2-US advisers reject new use for J&J/ Bayer's Xarelto
* FDA advisers concerned about missing data, bleeding risks
-
US FDA advisers rebuff J&J/ Bayer Xarelto heart drug
SILVER SPRING, Md., May 23 (Reuters) - A U.S. advisory panel rebuffed Johnson & Johnson's blood thinner, meant to reduce the risk of new heart attacks and strokes in people with heart problems.
-
Bayer ( BAYRY .PK) and Onyx Pharmaceuticals (ONXX) announce a Phase 3 trial of Nexavar tablets in patients with certain lung cancers did not meet its primary endpoint of improving overall survival.
Bayer ( BAYRY .PK ) and Onyx Pharmaceuticals ( ONXX ) announce a Phase 3 trial of Nexavar tablets in patients with certain lung cancers did not meet its primary endpoint of improving overall survival. Post your comment!
-
Interest Growing In Cancer Stem Cell Biotechs
By A John Hodge : In two weeks more than 25,000 cancer specialists will come together at the annual ASCO meeting in Chicago. There will be 1,000's of scientific abstracts released, and investors will pay close attention as the meeting always produces a number of market moving developments. I am ...
-
TEXT-Fitch revises Bayer's outlook to positive;afrms at 'A-'
(The following statement was released by the rating agency)
-
UPDATE 1-India's Piramal Healthcare to buy U.S. firm to boost R&D
… Piramal Healthcare has agreed to buy a U.S.-based healthcare data provider for $635 million to boost research and development, the company said on Wednesday, a month after it acquired the new molecules division of Germany's Bayer 's .
-
China Biotech In Review: Surgical Instrument Acquisition Takes Mindray Into New Territory
… ChinaBio and EBD Group report that over 700 industry leaders are set to attend the conference, including Aosaikang, AstraZeneca, Bayer HealthCare, BeiGene, Boehringer Ingelheim, Eli Lilly, Fosun Pharma, Furen Pharma, Hanmi Pharmaceutical, Hengrui Pharmaceuticals …
-
UPDATE 1- Bayer mulls diabetes device unit sale -sources
FRANKFURT, May 9 (Reuters) - Germany's largest drugmaker Bayer is considering the sale of its blood glucose meters business as it offers few synergies with its other healthcare activities, two people familiar with the matter said on Wednesday.
-
New Morningstar Analyst Report for Biogen Idec Inc
… business development strategies and pipeline prioritization, from which Biogen Idec could benefit. In addition, his unit at Bayer BAY marketed a hemophilia product that Biogen hopes to compete with. Two key new hires to management should also serve Biogen …